US FDA Tried, But Failed, To Take Compounding Issue Off The Table At Makena AdComm

 
• By Sue Sutter
Mortar
Withdrawal of Makena will drive clinicians and patients to seek out compounded versions of 17P, panelists said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers